Aadi bioscience to participate in panel discussion on tumor-agnostic development at cowen's 42nd annual health care conference

Los angeles, march 01, 2022 (globe newswire) -- aadi bioscience, inc. (“aadi”) (nasdaq:aadi), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that founder, chief executive officer and president, neil desai, ph.d., will participate in a panel discussion on tumor-agnostic development and one-on-one investor meetings at cowen's 42nd annual health care conference, to be held virtually march 7-9, 2022.
AADI Ratings Summary
AADI Quant Ranking